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At least half of all known 
drug-resistant tuberculosis 
(DR-TB) patients in the Port 
Elizabeth area (and possibly 
the entire Eastern Cape) are 
being treated with too few drugs, fuelling 
the spread of extensively drug-resistant 
(XDR)-TB and condemning them to death.
Similar dynamics, though not quite as 
alarming, pertain in KwaZulu-Natal and to a 
lesser extent in the Western Cape. An atypi-
cal (Beijing) strain of multiple-drug-resis-
tant (MDR)-TB, first detected by researchers 
at Stellenbosch University 2 years ago, is 
being created via a ‘one-size-fits-all’ system 
of de centralised, nurse-led TB clinics with 
an insufficient array of drugs and wholly 
in adequate expertise. In the Eastern Cape, the 
situation is being worsened by a woeful lack 
of local political will and/or understanding – 
resul ting in a virulent, ‘export-ready’ budget- 
crippling potential domestic time bomb. 
Researchers spoken to by Izindaba say that 
patients carrying this ‘aberrant’ pre-XDR 
MDR strain and/or the ensuing full-blown 
XDR are being detected in significant 
numbers in the Western Cape metropole, the 
primary destination for the Eastern Cape’s 
huge migrant worker popu lation. The Beijing 
strain is one mutation away from XDR and is 
being driven by treatment with an insufficient 
array of drugs. Izindaba has reliably learnt 
that the National Health Laboratory Service 
(NHLS) in Port Elizabeth conducted a Line 
Probe Assay (using the latest Hain LifeSciences 
technology) on two locally predominant 
MDR-TB strains, one in particular (Beijing) 
described as ‘pre-programmed to become 
XDR’. The conclusion of their lab technicians? 
The Port Elizabeth (PE) metropole, in parti-
cular, has a ‘real problem’.
When slower is better
‘It appears to be fuelled by our patients being 
put onto a standard regimen of treatment 
in which very few drugs are effective,’ one 
source said. An infectious diseases doctor 
working in the Eastern Cape explained that 
nurses could wait for up to 6 weeks for culture 
results to confirm the DR strain. This ‘archaic’ 
confirmation followed the 2-hours-or-less 
GeneXpert result confirming rifampicin 
resistance. While the samples were at the 
laboratory to confirm or identify additional 
resistance markers by culture, nurses and 
doctors were ‘blindly’ putting patients onto 
standard MDR-TB treatment – inadequate 
to treat many of the circulating strains and 
thus amplifying resistance. Médecins Sans 
Frontières (MSF) is strengthening its MDR 
drug regimen in the Western Cape, leading 
the way in combating this new pre-XDR 
strain. (National policy on TB treatment is to 
get as many patients onto treatment as soon 
as possible and to refer patients, but some 
experts believe there is insufficient emphasis 
on, and education about, the multiple 
complexities of drug resistance.) The 
national guidelines encourage NGOs and 
provincial clinics to promote nurse-initiated 
DR-TB treatment based on single GeneXpert 
results. However, most healthcare workers, 
including many doctors, do not understand 
how to tailor MDR treatment based on 
mutational analysis, resulting (in the case of 
the Beijing strain) in the rough equivalent of 
pouring petrol onto a veld fire, the Izindaba 
sources claim.
First doing more  
harm …
One as yet unpublished research paper on 
the aberrant MDR-TB strain shows that 25% 
of the PE laboratory samples examined are 
pre-XDR and 25% are full-blown XDR  – 
clearly demonstrating that half of all the 
cases scrutinised are being inadequately/
incorrectly treated.
A doctor source at the coalface explained 
that ‘essentially treatment has selected this 
strain out – the issue here is the current 
system not dealing with the current problem’. 
He said that infrastructure issues, misguided 
provincial budget allocation, insufficient 
training and staff, and a general lack of MDR 
treatment knowledge on the part of both 
nurses and doctors aggravated matters. The 
latest available data from the Jose Pearson TB 
Hospital in PE show that in 2011, just 35% of 
MDR TB patients who completed 24 months 
of treatment remained cured after a year, 
while only 12% of XDR-TB patients who 
completed 24 months of treatment remained 
cured a year later. In 2012, this treatment 
‘success’ for MDR patients dropped to 29% 
and for XDR patients to 9%. This is roughly 
in line with much of the published data. 
(The implication is that the remainder have 
died, will die or have been lost to follow-up, 
unless the debilitated survivors can quickly 
access the latest drugs now coming on line – 
bedaquiline and linezolid.)
According to the treatment register at 
the Jose Pearson TB Hospital, there were 
24 confirmed cases of XDR-TB (of which 
17 were HIV-positive) in the last quarter of 
last year. The number of patients started on 
treatment in the first quarter of 2014 was 48. 
The hospital sees up to 15 new cases of XDR-
TB per month, draining a huge area in the 
western part of the province – from Graaff 
Reinet to Port Alfred and from Humansdorp 
to Kareedouw. The clinicians emphasised 
that this probably represents the ‘tip of the 
iceberg’ in terms of actual MDR/XDR-TB 
prevalence. Many TB sufferers never make it 
to a clinic or present too late, having ignored 
the initial night sweats or the persistent 
cough. ‘TB is a classic for presenting too late. 
Active case finding needs to be drastically 
addressed,’ says Prof. Rob Warren, associate 
professor in the Department of Medical 
Biochemistry at Stellenbosch University, 
whose team first identified the aberrant pre-
XDR-TB Beijing strain at the heart of the 
latest development.
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‘A tide … when taken at 
the flood …’
The Eastern Cape coalface doctor warned: 
‘We’re at a crossroads. If we don’t have a 
complete revamp of how we approach this 
problem, we’ll lose a golden opportunity to 
really make a difference. We have a threshold; 
something needs to be done now. If we 
continue blindly on, we’ll expand resistance 
to the new drugs we have ...’ Chief among the 
solutions, he believes, is a centralised system 
to allow the appropriate use of new drugs in a 
regulated manner based on better diagnostics 
with good monitoring and follow-up (at least 
until better training and systems are in place 
to allow more widespread use of the new 
drug resources). He said patients needed 
to be put on the correct therapy as soon as 
possible, with much-improved case-finding 
and follow-up.
Eastern Cape a TB 
treatment ‘black hole’
One doctor typified the Eastern Cape (when 
compared with the other high-TB-burden 
provinces of the Western Cape and KwaZulu-
Natal) as ‘a black hole – it’s left up to poorly 
trained people to implement a very difficult 
programme’. The historical/political context 
is showing. The other two provinces have ‘a 
lot of academic research going on and use 
their resources more efficiently. In the Eastern 
Cape programmes are poorly applied and 
badly implemented – to the point where they 
don’t work. My sense is that things are getting 
worse.’ Eastern Cape doctors said that staff 
shortages and a lack of ongoing monitoring 
have rendered contact tracing and follow-up 
wholly ineffective.  Warren’s team found that 
the Beijing MDR/XDR-TB strain was causing 
a huge amount of primary transmission, not 
only within a specific HIV-positive cohort 
of patients, but across the board. His team’s 
research centres on novel strategies to reduce 
the time-to-detection period of both drug-
sensitive and DR-TB – and to understand the 
causative agents of the disease better. Their 
goal is to ‘develop a foolproof diagnostic 
method that can be used by anyone, anywhere’.
TB diagnosis ‘behind the 
research curve’
The current TB diagnostic method remains 
an arduous process that requires the patient 
to present to the health facility for screening, 
diagnosis and treatment. Sputum samples are 
sent to a peripheral laboratory for GeneXpert 
testing and to a central laboratory for drug 
susceptibility testing. The patient is therefore 
not present when the results arrive. Up to 20% 
of patients do not return at all for their results, 
and even top government TB Directorate 
officials admit that the systems for tracing 
them are weak. On testing, Warren observed: 
‘The tools are out there. There’s the first-line 
probe and then the probe for second-line 
drugs – if we implemented the second-line 
test, we could probably reduce the [laboratory 
test] turn-around time from around 50 days 
to 3 days.’ The test is not perfect yet (a reason 
given for its low use in spite of its being 
approved by the World Health Organization 
(WHO)), but it picks up over 80% of second-
line resistance (both are Hain LifeSciences 
assays). Warren emphasised that in the South 
African (SA) TB ‘outbreak’ context, the 
success rate would probably be much higher 
because outbreaks generally contain the same 
mutations, making identification much easier.
An Izindaba canvassing of some top TB res-
earchers revealed that they do not necessarily 
have ‘the ear’ of the National Department of 
Health (NDoH). Said Warren: ‘Unfortunately 
there isn’t good liaison between research, 
and policy and practice. Things filter slowly 
through the academic journals into their 
expert group discussions where they may or 
may not take on an idea and put it forward.’
XDR-TB on the increase 
nationally
Between 2007 and 2012, SA’s recorded cases 
of MDR-TB (i.e. resistant to at least two of 
the primary drugs used to combat standard 
TB) almost doubled. SA has the highest 
incidence of TB among the 22 high-burden 
countries (860/100 000), and when adjusted 
for population, it outdoes India and China. 
According to 2012 government figures, just 
42% of patients diagnosed with MDR-TB 
began treatment. Observes Dr Gilles van 
Cutsem, MSF’s medical co-ordinator for SA 
and Lesotho: ‘We have in SA one of the only 
rising epidemics of drug-sensitive TB and 
DR-TB. And we’re not doing very well at 
detecting it and treating it.’
In a highly cited paper[1] co-authored 
by Prof. Keertan Dheda, Head of the Lung 
Infection and Immunity Unit in the Uni versity 
of Cape Town’s Lung Institute, the budgetary 
implications of not responding appropriately 
to the DR-TB challenge are daunting. 
Assuming proper adherence to national 
DR-TB management guidelines, the current 
per patient cost of XDR-TB is ZAR303 508 
(USD26 392), four times greater than that of 
MDR-TB at ZAR77 878 (USD6 772), and 103 
times greater than drug-sensitive TB at ZAR2 
955 (USD257). Despite DR-TB’s comprising 
only 2.2% of the case burden, it consumed 
32% of the total estimated 2011 national TB 
budget of ZAR2.5 billion (USD218 million). 
A frightening 45% and 25% of the DR-TB 
costs were attributed to anti-TB drugs and 
hospitalisation, respectively. XDR-TB 
consumed 28% of the total DR-TB diagnosis 
and treatment costs. Laboratory testing and 
anti-TB drugs comprised the majority (71%) 
of MDR-TB costs, while hospitalisation and 
anti-TB drug costs comprised the majority 
(92%) of XDR-TB costs. A decentralised XDR-
TB treatment programme could potentially 
reduce costs by ZAR79 695 (USD6 930) (26%) 
per case and reduce the total amount spent on 
DR-TB by 7%, the authors conclude.[1]
Prof. Keertan Dheda, Head of Pulmonology, Uni­
versity of Cape Town and Groote Schuur Hospital.
Dr Norbert Ndjeka, head of the National MDR­
TB Directorate.
Assuming proper adherence to 
national DR-TB management 
guidelines, the current per patient 
cost of XDR-TB is ZAR303 508 
(USD26 392), four times greater 
than MDR-TB at ZAR77 878 
(USD6 772), and 103 times 
greater than drug-sensitive TB at 
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SA’s TB control ‘a 
comedy of errors’
Both Warren and Dheda have emphasised 
that unless the drug-susceptible ‘TB tap’ is 
turned off, DR-TB will continue to grow. 
Dheda’s work currently centres on creating 
an effective new combination regimen for 
DR-TB.
In a paper published in the South African 
Respiratory Journal,[2] Warren and his co- 
authors bluntly say that their review of TB 
statistics ‘suggests that the current National 
Tuberculosis Control Programme is unable 
to curb the emergence and spread of this 
difficult-to-treat epidemic’. The country’s TB 
control history was ‘a comedy of errors’, 
which more modern technology could 
have helped avoid. ‘It is therefore essential 
that we learn from these mistakes and use 
current knowledge to design diagnostic 
algorithms and treatment guidelines that 
prevent acquisition of resistance and 
ensure improved treatment outcomes,’ they 
conclude.[2] Warren emphasised that he was 
not blaming anyone in the current national 
TB Directorate, but merely pointing to the 
treatment mistakes of the past that they were 
now saddled with.
Neither Dr Norbert Ndjeka, head of the 
MDR-TB Directorate, nor Dr Lindiwe Mvusi, 
National TB Directorate chief, had seen the 
PE NHLS research paper – but they were 
eager to study it. Ndjeka said the national 
guidelines ‘clearly stated’ that the standard-
ised regimen was for newly diagnosed MDR-
TB patients only. MDR-TB patients exposed 
to second-line drugs, pre-XDR-TB and 
XDR-TB were treated with an ‘individualised 
regimen’ (however, Izindaba established 
that this was only after drug susceptibility 
results were made available after a wait 
that could take 6 weeks – again, it is in this 
time that patients are being ‘undertreated’). 
Ndjeka denied that many clinicians lacked 
sufficient knowledge, describing them as 
‘well trained, and educated’. He said he was 
due to hold a workshop with his provincial 
staff and clinicians in Johannesburg in mid- 
to late February – and invited Izindaba 
to bring Warren and its other sources to 
address them. He described the Jose Pear-
son Hospital MDR/XDR figures cited as 
‘another gross inaccuracy’, saying last year’s 
WHO Global Tuberculosis Report had SA’s 
2011 cohort analysis and that the 2012 report 
was still incomplete, but due for finalisation 
this April.
Ndjeka said that SA was a ‘very high’ 
MDR-TB country, and his directorate had 
consulted the ‘best brains in the country’ 
on this issue. ‘We cannot work with each 
and everybody, though the top ones are 
in constant communication with us – I 
can provide proof of this,’ he asserted. 
He said that describing the country’s TB 
control history as a ‘comedy of errors’ was 
‘malicious’. ‘We need experts who provide 
solutions, given the little existing evidence,’ 
he added. Mvusi conceded that the Hain Line 
Probe Assay, version 2, would ‘help greatly in 
reducing the waiting time for con firmatory 
first- and second-line drug suscep tibility 
testing because the patient could then be 
switched to the appropriate regimen earlier’. 
Ndjeka said that linezolid and bedaquiline 
were being introduced ‘in a very responsible 
manner’ in the public sector, SA being 
the first TB programme in the world to 
introduce new agents in about 40 years.
Eastern Cape admits 
there’s a problem – but 
it’s ‘being addressed’
An Eastern Cape health department spokes-
man revealed that bedaquiline had already 
been ‘responsibly’ introduced at the Jose 
Pearson Hospital (and a few other selected 
hospitals nationwide), and ‘so far no adverse 
events have been reported’. TB clinicians 
across the country had just met to discuss the 
scale-up of linezolid and bedaquiline. The 
Jose Pearson Hospital ‘performance figures’ 
quoted by Izindaba were ‘acknowledged’, but 
the data were ‘currently being cleaned up to 
April this year before being submitted as final 
to the WHO’. He said that the province had 
a very high MDR-TB burden and admitted 
that treatment outcomes were poor – but a 
‘lot of progress’ in managing the disease had 
been made in recent years. The NHLS had 
produced evidence that positive GeneXpert 
rifampicin-resistant cases were more likely 
to be MDR-TB, ‘hence our guidelines 
recommend starting MDR-TB treatment, 
taking a sample for confirmatory test through 
the Line Probe Assay or conventional drug 
susceptibility testing’. He repeated the NDoH 
assertion that MDR-TB patients exposed to 
second-line TB drugs, pre-XDR TB patients 
and XDR-TB patients were treated with 
an individualised drug regimen. An expert 
provincial MDR-TB committee met every 
quarter to review and discuss complicated 
cases and facilitate/regulate access to the 
new drugs. The reported increase in DR-TB 
in the province between 2007 and 2012 was 
actually an indication of intensified case 
finding and better diagnostic technology. 
Active steps to address the challenges inclu-
ded partnering with the NHLS to improve 
the response to positive DR-TB results with 
rapid follow-up diagnostics. The DR-TB 
decentralisation programme involved ten 
hospitals, with intensive training of health-
care workers on MDR-TB management 
being accelerated, while outreach vehicles 
had been hired to address late presentation 
of patients and improve case finding and 
contact tracing. Four hospitals were either 
under construction or renovation to comply 
with national infection prevention and 
control guidelines. 
Although Izindaba did not source its 
most alarming data directly from the PE 
laboratory, technicians there received a stern 
warning: ‘Permission is required to conduct 
research or make use of departmental data/
information – this being granted only on 
condition that these findings are shared with 
provincial health management before being 
presented on any platform.’
Izindaba has chosen to withhold the names 
of some of its Eastern Cape sources, who said 
they fear becoming targets of angered local 
officialdom – historically a common anxiety 
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